Concerning glycemic control, after excluding the patient with severe hyperglycemia on oral semaglutide, delta A1c from baseline was still significantly higher with injectable ( 1.1 1.3) than with oral ( 0.5 1.9) formulation
CrossRef Validation and Comparison of PROMISE and CONFIRM Model to Predict High-Risk Coronary Artery Disease in Symptomatic and Diabetes Mellitus Patients Hantao Jiang, Jinping Feng, Chao Feng, Pei Ren, Kai Ren, Ying Jin, Jia Zhou Reviews in Cardiovascular Medicine.2022;[Epub] CrossRef The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review Aikaterini Eleftheriadou, Scott Williams, Sarah Nevitt, Emily Brown, Rebecca Roylance, John P
Opportunity for Larger Settlements Due to the volume and weight of evidence presented in mass torts, settlements in these cases are often larger than individual lawsuits, offering plaintiffs a greater chance at substantial compensation
The SEMALEAN study (2025), which tracked 106 patients on semaglutide 2.4 mg over 12 months using DXA body composition scans, found that while average weight loss was 13% at 12 months, significant variations in the ratio of fat loss to muscle loss occurred between patients based on protein intake and physical activity
